Skip to main content

Harmony Biosciences Holdings, Inc.

corporate_fare Company Profile

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ·Life Sciences·CIK 0001802665

The company is a neuroscience company focused on rare neurological diseases, with a portfolio covering sleep/wake, rare epilepsy, and neurobehavioral conditions. Its lead product is WAKIX® (pitolisant), a therapy that enhances histamine signaling in the brain by binding to H3 receptors. The company acquired exclusive commercialization rights for pitolisant from Bioprojet Société Civile de Recherche ("Bioprojet") in July 2017. WAKIX was initially approved by the FDA in 2019 for excessive daytime sleepiness ("EDS") in adult narcolepsy patients, followed by approvals for cataplexy in adult patients in 2020, EDS in pediatric patients six years and older in 2024, and cataplexy in pediatric patients six years and older in 2026. WAKIX is the only FDA-approved narcolepsy treatment not scheduled as a controlled substance by the U.S. Drug Enforcement Administration ("DEA"). The company is also exploring pitolisant in late-stage clinical programs for idiopathic hypersomnia ("IH"), Prader-Willi syndrome ("PWS"), and myotonic dystrophy type 1 ("DM1"). In July 2022, the company obtained exclusive rights from Bioprojet to manufacture, develop, and commercialize next-generation pitolisant-based products in the United States and Latin America, including pitolisant Gastro-Resistant ("Pitolisant GR") and pitolisant High-Dose ("Pitolisant HD"), both currently in clinical development. In April 2024, the company expanded into orexin science through a sublicense agreement with Bioprojet for BP1.15205, an orexin 2 receptor agonist in preclinical development for narcolepsy and other potential indications.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for HRMY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for HRMY spans 10-Q, 8-K, 144, DEF 14A.

Recent high-impact activity:

  • Harmony 10-Q: Q3 Revenue $268.9M, $1.05B Cash, R&D Up 30% on MSN Milestone
  • Harmony Q3: WAKIX Revenue $268.9M, Guidance Reiterated, BP-205 MAD Data Positive
  • Harmony Biosciences Posts 81-Cent Q3 EPS
  • Wakix Patent Closing Arguments Send Harmony Shares Down 7%
  • Harmony Biosciences Taps Peter Anastasiou as CEO, Reaffirms $1B+ 2026 Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$868.45M
Net Income
$158.69M
Diluted EPS
$2.71
Op. Cash Flow
$348.2M
Free Cash Flow
$347.89M
Gross Profit
$670.11M
Operating Income
$208.47M
Cash & Equivalents
$752.5M
Total Debt
$163.66M
Debt / Equity
0.19×
Net Margin
18.3%
Shares Outstanding
57.73M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-018859

Short Interest & Short Volume

5.63 days to cover

FINRA reported short interest of 6,664,944 shares in HRMY as of the October 30, 2026 settlement, a 23.1% increase from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 60.1% of HRMY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,664,944 shares as of October 30, 2026
Change vs prior period▲ 23.1%
Days to cover5.63 at avg daily volume of 1,183,552
Daily short volume (FINRA facilities)60.1% of 196,128 shares on November 20, 2026
5-day average short volume55.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$32.43 -0.49% today
52-week range · as of 2026-11-04 $25.9 – $43.49
Market cap
$1.91B
Volume
582.6K (0.5× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.94
Real-time Price: $32.43 info
Change: -$3.51 (-10%) info
Market Cap: $1.914B info
HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $32.43 info
Change: -$3.75 (-10%) info
Market Cap: $1.914B info
HRMY
Nov 04, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $32.43 info
Change: -$4.07 (-11%) info
Market Cap: $1.914B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $32.43 info
Change: -$3.60 (-10%) info
Market Cap: $1.914B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $32.43 info
Change: -$5.97 (-16%) info
Market Cap: $1.914B info
HRMY
Oct 12, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $40.28
Real-time Price: $32.43 info
Change: -$7.85 (-19%) info
Market Cap: $1.914B info
HRMY
Aug 07, 2026, 4:48 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $38.41
Real-time Price: $32.43 info
Change: -$5.98 (-16%) info
Market Cap: $1.914B info
HRMY
Aug 05, 2026, 6:56 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $37.05
Real-time Price: $32.43 info
Change: -$4.62 (-12%) info
Market Cap: $1.914B info
HRMY
Aug 04, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.75
Real-time Price: $32.43 info
Change: -$4.32 (-12%) info
Market Cap: $1.914B info
HRMY
Aug 04, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.25
Real-time Price: $32.43 info
Change: -$4.82 (-13%) info
Market Cap: $1.914B info
HRMY
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $34.10
Real-time Price: $32.43 info
Change: -$1.67 (-5%) info
Market Cap: $1.914B info
HRMY
Jul 16, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.91
Real-time Price: $32.43 info
Change: -$2.48 (-7%) info
Market Cap: $1.914B info
HRMY
Jul 16, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $34.80
Real-time Price: $32.43 info
Change: -$2.37 (-7%) info
Market Cap: $1.914B info
HRMY
Jun 30, 2026, 4:04 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $36.41
Real-time Price: $32.43 info
Change: -$3.98 (-11%) info
Market Cap: $1.914B info
HRMY
Jun 26, 2026, 4:17 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $35.47
Real-time Price: $32.43 info
Change: -$3.04 (-9%) info
Market Cap: $1.914B info
HRMY
May 07, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.80
Real-time Price: $32.43 info
Change: +$2.63 (+9%) info
Market Cap: $1.914B info
HRMY
Apr 14, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.97
Real-time Price: $32.43 info
Change: +$3.46 (+12%) info
Market Cap: $1.914B info
HRMY
Apr 14, 2026, 8:09 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $29.04
Real-time Price: $32.43 info
Change: +$3.39 (+12%) info
Market Cap: $1.914B info
HRMY
Apr 03, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $27.78
Real-time Price: $32.43 info
Change: +$4.65 (+17%) info
Market Cap: $1.914B info
HRMY
Apr 02, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.45
Real-time Price: $32.43 info
Change: +$4.98 (+18%) info
Market Cap: $1.914B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets